ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the addition of two senior executives to its executive management team. Eric Feldman, M.D., a specialist in leukemia and bone marrow disorder therapies, has been appointed Vice President of Clinical Development. Christian Dinneen-Long, an attorney with deep experience in the biotechnology industry, has been appointed Vice President and Corporate Counsel.
“We are pleased to bolster the GlycoMimetics executive team with the addition of these two very accomplished leaders, and we look forward to leveraging their expertise as we continue to cultivate our pipeline of novel, small-molecule glycomimetic therapeutics,” said Chief Executive Officer Rachel King. “Eric’s extensive background in acute myeloid leukemia (AML) clinical development and Christian’s strong governance and transactional experience will both be invaluable to our corporate advancement, particularly as we move our uproleselan AML program through late-stage clinical trials.”
Dr. Feldman is internationally recognized for his work in the development of new therapies for the treatment of leukemias and related bone marrow disorders. He is the past Editor-in-Chief of the journal Leukemia Research, Professor of Medicine and Director of the Hematologic Malignancies Service at Weill Medical College of Cornell University. In industry, he was Distinguished Clinical Research Scientist at Seattle Genetics, and he most recently served as Chief Medical Officer at Amphivena Therapeutics, Inc. Dr. Feldman will report to GlycoMimetics Senior Vice-President of Clinical Development and Chief Medical Officer Helen Thackray.
Mr. Dinneen-Long has over 15 years of in-house legal experience at several public biotech companies, in addition to experience early in his career at a major Washington, DC law firm. He most recently served as Senior Counsel at AstraZeneca/MedImmune, where he supported strategic initiatives, pipeline programs and major business development transactions. Mr. Dinneen-Long will also serve as GlycoMimetics’ Corporate Secretary and will report to CEO Rachel King.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics’ most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics’ wholly owned drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including a company-sponsored Phase 3 trial in relapsed/refractory AML. GlycoMimetics has also completed a Phase 1 clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.